Human health diagnostics, a business increasingly dominated by genetics-based analysis, is “a multibillion-dollar [annual] market for sure,” said Matt Posard, senior vice president and general manager for translational and consumer genomics at Illumina. “This is absolutely where science is going, where medicine is going. If you look at all the applications for knowing one’s own genome, it has all the characteristics of a revolution in molecular diagnostics.”
Posard said 14-year-old Illumina is open to one day expanding its alliance with Partners to create an independent business, but he stressed the partnership is still in an early stage.
“We have a common vision for the future,” he said. “A physician will have a clinical question that current technology can’t address, and we can provide a medically validated answer.”
Robert Weisman can be reached at email@example.com.